

Kei Moriya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5984700/publications.pdf>

Version: 2024-02-01

92
papers

1,850
citations

331670

21
h-index

315739

38
g-index

93
all docs

93
docs citations

93
times ranked

2813
citing authors

#	ARTICLE	IF	CITATIONS
1	Bile acid dysmetabolism in the gut-microbiota-liver axis under hepatitis C virus infection. <i>Liver International</i> , 2022, 42, 124-134.	3.9	11
2	Rare case of early jejunal cancer with laterally spreading tumor-like appearance. <i>Digestive Endoscopy</i> , 2022, 34, 246-246.	2.3	0
3	Laser-cut-type versus braided-type covered self-expandable metallic stents for distal biliary obstruction caused by pancreatic carcinoma: a retrospective comparative cohort study. <i>Clinical Endoscopy</i> , 2022, 55, 434-442.	1.5	4
4	Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute-on-chronic liver failure development and prognosis in patients with liver cirrhosis. <i>Hepatology Research</i> , 2022, 52, 390-400.	3.4	7
5	Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis. <i>Indian Journal of Gastroenterology</i> , 2022, 41, 169-180.	1.4	5
6	ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability. <i>Journal of Clinical Medicine</i> , 2022, 11, 1835.	2.4	8
7	Endotoxin Activity Reflects an Increase in Body Temperature in Cirrhotic Patients With Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy. <i>In Vivo</i> , 2022, 36, 1477-1484.	1.3	0
8	The association of histological progression with biochemical response to ursodeoxycholic acid in primary biliary cholangitis. <i>Hepatology Research</i> , 2021, 51, 31-38.	3.4	5
9	Chronic active EBV infection in refractory enteritis with longitudinal ulcers with a cobblestone appearance: an autopsied case report. <i>BMC Gastroenterology</i> , 2021, 21, 6.	2.0	4
10	Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4001-4013.	3.6	11
11	Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 629.	2.4	1
12	Current status of hepatitis test recognition and an attempt of an efficient screening test in an area with a low implementation rate of hepatitis screening. <i>Acta Hepatologica Japonica</i> , 2021, 62, 89-91.	0.1	1
13	Sulforaphane ameliorates ethanol plus carbon tetrachloride-induced liver fibrosis in mice through the Nrf2-mediated antioxidant response and acetaldehyde metabolism with inhibition of the LPS/TLR4 signaling pathway. <i>Journal of Nutritional Biochemistry</i> , 2021, 89, 108573.	4.2	58
14	The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects. <i>Cells</i> , 2021, 10, 575.	4.1	13
15	Efficacy of Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumor. <i>Clinical Endoscopy</i> , 2021, 54, 371-378.	1.5	16
16	Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6921.	4.1	16
17	Zinc Administration and Improved Serum Markers of Hepatic Fibrosis in Patients with Autoimmune Hepatitis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2465.	2.4	6
18	Clinical Significance of Gamma-Glutamyltranspeptidase Combined with Carbohydrate-Deficient Transferrin for the Assessment of Excessive Alcohol Consumption in Patients with Alcoholic Cirrhosis. <i>Medicines (Basel, Switzerland)</i> , 2021, 8, 39.	1.4	4

#	ARTICLE	IF	CITATIONS
19	The association between sarcopenia and endotoxin in patients with alcoholic cirrhosis. <i>Medicine (United States)</i> , 2021, 100, e27212.	1.0	10
20	A rare case of refractory and severe duodenal ulcers associated with olmesartan. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 657-658.	1.0	1
21	Angiotensin Receptor Blockers Potentiate the Protective Effect of Branched-Chain Amino Acids on Skeletal Muscle Atrophy in Cirrhotic Rats. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2100526.	3.3	5
22	The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria. <i>Journal of Clinical Medicine</i> , 2021, 10, 4838.	2.4	4
23	Association between Equol Production Status and Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11904.	4.1	6
24	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 30.	1.8	0
25	Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity. <i>World Journal of Gastroenterology</i> , 2021, 27, 8323-8342.	3.3	10
26	Effect of furosemide on muscle cramps in patients with liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 76-81.	2.8	6
27	Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia. <i>Digestive Diseases</i> , 2020, 38, 329-334.	1.9	5
28	Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7588.	4.1	10
29	Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5589.	4.1	21
30	Accuracy of Fibrosis-4 Index in Identification of Patients with Cirrhosis Who Could Potentially Avoid Variceal Screening Endoscopy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3510.	2.4	7
31	Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure. <i>Journal of Clinical Medicine</i> , 2020, 9, 1467.	2.4	8
32	Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1635.	2.4	11
33	Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2'-deoxycytidine in Hepatic Stellate Cells. <i>Biology</i> , 2020, 9, 117.	2.8	2
34	Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective single-center study. <i>Hepatology Research</i> , 2020, 50, 1101-1105.	3.4	5
35	Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis. <i>Microorganisms</i> , 2020, 8, 925.	3.6	18
36	Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. <i>Hepatology Research</i> , 2020, 50, 840-852.	3.4	46

#	ARTICLE	IF	CITATIONS
37	Chronic Alcohol Consumption is Inversely Associated with Insulin Resistance and Fatty Liver in Japanese Males. <i>Nutrients</i> , 2020, 12, 1036.	4.1	9
38	Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients. <i>Antibiotics</i> , 2020, 9, 145.	3.7	33
39	Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2164.	4.1	12
40	Association between ADAMTS13 activity and VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2020, 26, 7232-7241.	3.3	11
41	Effect of L-carnitine on health-related quality of life in patients with liver cirrhosis. <i>Biomedical Reports</i> , 2020, 13, 1-1.	2.0	7
42	Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 985-995.	1.8	12
43	Novel oral plasminogen activator inhibitor-1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats. <i>Molecular Medicine Reports</i> , 2020, 22, 2948-2956.	2.4	10
44	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 1-1.	1.8	2
45	VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2019, 19, 167.	2.0	20
46	Performance of laboratory tests for detection for <i>Clostridioides difficile</i> : A multicenter prospective study in Japan. <i>Anaerobe</i> , 2019, 60, 102107.	2.1	7
47	Late-Evening Snack with Branched-Chain Amino Acid-Enriched Nutrients Does Not Always Inhibit Overt Diabetes in Patients with Cirrhosis: A Pilot Study. <i>Nutrients</i> , 2019, 11, 2140.	4.1	4
48	TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats. <i>Cells</i> , 2019, 8, 1153.	4.1	16
49	Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient L-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2724.	4.1	18
50	Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis. <i>Hepatology Research</i> , 2019, 49, 1147-1161.	3.4	9
51	Blocking development of liver fibrosis augments hepatic progenitor cell-derived liver regeneration in a mouse chronic liver injury model. <i>Hepatology Research</i> , 2019, 49, 1034-1045.	3.4	5
52	Identification of clinical risk factors for histological progression of primary biliary cholangitis. <i>Hepatology Research</i> , 2019, 49, 1015-1025.	3.4	9
53	<i>Clostridioides (Clostridium) difficile</i> infection burden in Japan: A multicenter prospective study. <i>Anaerobe</i> , 2019, 60, 102011.	2.1	47
54	Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis. <i>Hepatology Research</i> , 2019, 49, 232-238.	3.4	9

#	ARTICLE	IF	CITATIONS
55	Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis. <i>Hepatology Research</i> , 2019, 49, 284-295.	3.4	25
56	Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 381-389.	8.9	11
57	Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 887-897.	2.0	5
58	ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 424-435.	2.0	8
59	Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 65-73.	8.9	4
60	Gut Dysbiosis Associated With Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2018, 67, 869-877.	5.8	130
61	Platelet hyperaggregability is associated with decreased ADAMTS13 activity and enhanced endotoxemia in patients with acute cholangitis. <i>Hepatology Research</i> , 2018, 48, E52-E60.	3.4	10
62	Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. <i>International Journal of Cancer</i> , 2018, 142, 1712-1722.	5.1	136
63	Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 741-749.	1.4	12
64	Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats. <i>BMC Cancer</i> , 2018, 18, 1164.	2.6	5
65	von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C. <i>United European Gastroenterology Journal</i> , 2018, 6, 1401-1409.	3.8	27
66	Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 2743-2750.	1.8	4
67	Glycogenic Hepatopathy in Type 1 Diabetes Mellitus. <i>Internal Medicine</i> , 2018, 57, 1087-1092.	0.7	10
68	Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein. <i>Cancer Letters</i> , 2018, 434, 120-129.	7.2	31
69	Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model. <i>Oncotarget</i> , 2018, 9, 28638-28651.	1.8	18
70	Treatment of long-segment Barrett's adenocarcinoma by complete circular endoscopic submucosal dissection: a case report. <i>BMC Gastroenterology</i> , 2018, 18, 16.	2.0	6
71	Liver fibrosis progression predicts survival in patients with primary biliary cirrhosis. <i>Hepatology Research</i> , 2017, 47, E178-E186.	3.4	14
72	Predictive parameter of tolvaftan effectiveness in cirrhotic ascites. <i>Hepatology Research</i> , 2017, 47, 854-861.	3.4	30

#	ARTICLE	IF	CITATIONS
73	Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis. Hepatology Research, 2017, 47, 1317-1328.	3.4	22
74	Periostin cross-reacts with the renin-angiotensin system during liver fibrosis development. Molecular Medicine Reports, 2017, 16, 5752-5758.	2.4	10
75	Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization. Oncology Letters, 2017, 14, 3028-3034.	1.8	16
76	Therapeutic strategies for alcoholic liver disease: Focusing on inflammation and fibrosis (Review). International Journal of Molecular Medicine, 2017, 40, 263-270.	4.0	49
77	Aortic Valve Replacement for the Management of Heyde Syndrome: A Case Report. Journal of Nippon Medical School, 2017, 84, 193-197.	0.9	9
78	Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B. World Journal of Gastroenterology, 2017, 23, 6705-6714.	3.3	14
79	Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World Journal of Gastroenterology, 2017, 23, 8355-8366.	3.3	85
80	Gastric granular cell tumor in a youth excised by endoscopic submucosal dissection : A case report and literature review. Acta Gastro-Enterologica Belgica, 2017, 80, 317-319.	1.0	2
81	Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats. Journal of Gastroenterology, 2016, 51, 1141-1149.	5.1	39
82	Therapeutic effect of dual oral therapy with daclatasvir and asunaprevir for chronic HCV patient with depression. Acta Hepatologica Japonica, 2016, 57, 496-498.	0.1	0
83	Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis. Journal of Gastroenterology, 2016, 51, 162-172.	5.1	30
84	DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis. World Journal of Hepatology, 2016, 8, 1194.	2.0	6
85	Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. Molecular Medicine Reports, 2015, 11, 1693-1700.	2.4	62
86	Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. Journal of Gastroenterology, 2014, 49, 481-491.	5.1	107
87	The Effect of Inflammatory Cytokines in Alcoholic Liver Disease. Mediators of Inflammation, 2013, 2013, 1-10.	3.0	183
88	Cotransplantation of Mouse Embryonic Stem Cells and Bone Marrow Stromal Cells following Spinal Cord Injury Suppresses Tumor Development. Cell Transplantation, 2009, 18, 39-54.	2.5	52
89	Embryonic stem cells reduce liver fibrosis in CCl ₄ -treated mice. International Journal of Experimental Pathology, 2008, 89, 401-409.	1.3	38
90	Impact of insulin resistance on the progression of chronic liver diseases. International Journal of Molecular Medicine, 2008, 22, 801-8.	4.0	26

#	ARTICLE	IF	CITATIONS
91	Embryonic stem cells develop into hepatocytes after intrasplenic transplantation in CCl4-treated mice. World Journal of Gastroenterology, 2007, 13, 866.	3.3	28
92	Disappearance of hepatic encephalopathy and improvement of liver function after surgical treatment of portal-systemic shunt in a patient with liver cirrhosis. Hepato-Gastroenterology, 2003, 50, 1128-32.	0.5	1